Cancer in our lives
Most of us are confronted with cancer at some point in our lives. But we are not alone.
The lifetime risk of discovering cancer is 38% in the U.S. population.
49.5% of those cases happen between the age of 55 and 74, an additional 14.1% between 45 and 54.
It is estimated that it takes 3 to 6 years from the first cell to the detected cancer.
Current screening methods only cover few cancers, are partly invasive and might lead to inconclusive results.
Liquid biopsy offers the chance to detect more cancers earlier and to improve your personal outcome.
- Reduce cancer screening to one blood draw a year.
How it works
- Every cancer has an epigenetic fingerprint, partly unique to you, partly unique to its kind.
- We detect traces of those fingerprints in your blood samples using machine learning.
- The strongest signal exists in newly diagnosed cancers.
- After successful treatment, the signal diminishes.
- If the signal comes back, this is a potential sign for a clinical recurrence.
- The signal alters by age, disease and between individuals. And it is diluted in liquid
biopsy compared to a tissue sample.
- Therefore, large training data sets are needed to detect those signals in individuals
with no previous history of cancer.
- With your help, we are creating those data sets.
What we do
1. We create a longitudinal data set for you.
This allows us to learn more about the changes over time.
2. We add your medical information and create labels.
This allows us to compare your data set with all other data sets.
3. We onboard customers with and without cancer.
This allows us to identify the changes specific to a cancer.
4. Customers with cancer receive monitoring twice a year.
Customers without cancer receive screening once a year.
5. Every single sample and every single data set is helpful.
To detect cancer early.
6. We offer you all available algorithms out there.
You benefit the most.
1. After signing up, you will receive a kit containing a blood collection system and tubes and a return box.
2. During your next medical appointment, your doctor takes the blood sample from you with our kit.
3. You put the tubes back into the stamped return box and send it to us immediately.
4. We extract the cell-free DNA from your blood sample and sequence it in our partner lab.
5. We add your new sequence to your data set and analyse it with help of our growing database.
6. You receive a report on your sample and development over time including medical instructions.
Start your journey now
Status quoTell us which screening you are looking for and receive the current recommendations.
Help us understand
Learn more about screening
ScreeningStart sequencing today, help us to understand healthy individuals and opt in on the benefits.
Once a year
Detect cancer early
MonitoringWe can't undo your cancer. But your story can become part of something bigger.
Twice a year
Monitor your cancer
In order to learn more about your personal stories, we encourage you to tell us as much as possible about your screening history. What tests you are looking for, which cancers frighten you and why, and how you imagine a perfect screening. We provide you with links to the current cancer screening recommendations in the U.S. or in Germany, but you have to talk to your primary care physician to perform those tests. Hopefully we are able to create some comfort by listening to you.
This category is for people who want to create their own methylation snapshots now. First of all, we recommend to follow all cancer screening guidelines in your country of residence. Secondly, it is important to realise that we cannot offer you a diagnostic tool to this point. We only can help you to capture your methylation snapshot now and enable you to potentially participate in the benefits in 2-3 years. We recommend one test per year and we expose your data set to our own as well as to 3rd party algorithms to advance research.
Consider your participation as donation to research with unknown results. If you depend on your funds, take care of yourself first and follow the existing guidelines. Regardless of your choice, we appreciate your interest in our company and in liquid biopsy.
This category is for people who want to use their own methylation snapshots for the monitoring of a cancer. As mentioned above, we recommend to follow all cancer screening guidelines in your country of residence and to perform the cancer treatment as discussed with your physicians. Do not alter your treatment in any way based on your interaction with us. And again, it is important to realise that we cannot offer you a diagnostic tool to this point. We only can help you to capture your methylation snapshots before and 2-6 weeks after treatment, followed by two tests a year. Potentially we are able to carve out the cancer signal from your own background noise and offer you an additional insight. But there is no guaranty.
Consider your participation as donation to research with unknown results. If you depend on your funds, take care of yourself first and follow the existing guidelines. Regardless of your choice, we appreciate your interest in our company and wish you the best for your treatment.
We solely focus on you and your needs. Therefore we believe that it is important to accompany you from your first thoughts of screening through a healthy and long life up to the point of potential cancer diagnoses and a high level of uncertainty. After a treatment we want to reassure you of therapy success or alert you if there seems to be an impending recurrence.
Yes. We are creating a personal baseline and monitor the changes in regard to the baseline. Especially in cancer patients the lack of before and/or after treatment results would destroy the opportunity to precisely detect a cancer signal.
No. We are not a medical grade diagnostic tool yet. Our results just offer you additional information. Consider it experimental in a legal sense. Your screening/treatment/follow-up must not be altered in any way due to your usage of our service.
No. At the moment we don’t have any data that would endorse this assumption. Nonetheless we believe that participation in the fight against cancer might offer you some inner satisfaction and it also helps others.
Definitely yes. Our goal is to start a clinical trial soon and to apply for FDA and CE approval later on. Still, we want to allow customers who are currently affected by cancer to benefit from that journey.
We believe that we are able to present initial results to you within 2-3 years starting from now (early 2019).
In our mind everybody who easily can afford to pay for the sequencing should consider to participate. Many people believe that liquid biopsy will be the next big diagnostic tool and those who are participating now have the chance to benefit from this development and also to shape many aspects of it. If you can’t afford to pay for the sequencing, we still encourage you to help us shape the medical landscape by joining our “share” category. Everyone of you is important to us.
Some cancers grow over long time frames from up to 10 years. Even if results would come in 9 years, you still might be benefiting from participation. Without data there won’t be any results. We are looking for early adopters and their needs will help us to tackle their most urgent needs.
If you are already affected by cancer, we especially value you as a customer to learn more about the specific methylation fingerprint of your cancer. We also try to track your cancer signal over time to give you more information about potential progress or residual disease.
We try to focus on solid cancers in early stages with existing surgical treatment options.
Yes, there are already some tests on the market. Most of these tests focus on a small niche like a therapy decision for a certain late stage cancer. They are mainly designed to fulfill the needs of healthcare providers and to fit into the existing decision schemes.
Yes. In several countries there are existing screening programs like for breast cancer or colorectal cancer. You also could get a variety of lab work or a whole-body MRI. Unfortunately these tests often lead to more questions than answers, which might lead to uncertainty, fear and subsequent unnecessary treatments. We firmly recommend to talk to physicians first and to seek their guidance.